Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice

Journal of Neurochemistry

Volumn 71, Issue 4, 1998, Pages 1635-1642

  Aubin, Nadine ^a   Curet, Olivier ^a   Deffois, Annie ^a   Carter, Chris ^a  

^a SANOFI   (France)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Aspirin; Mouse; Neurotoxicity; Parkinson's disease model; Salicylic acid

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ACETYLSALICYLIC ACID; BENZOIC ACID DERIVATIVE; DEXAMETHASONE; DICLOFENAC; DOPAMINE; HOMOVANILLIC ACID; HYDROXYL RADICAL; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LYSINE ACETYLSALICYLATE; NORADRENALIN; PARACETAMOL; PHENETHYLAMINE; SALICYLIC ACID; SCAVENGER; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRAIN LEVEL; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA;

EID: 0031661173     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71041635.x     Document Type: Article

References (48)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Radic. Biol. Med. 15, 181-186.
2. + neurotoxicity against rat dopaminergic neurons in culture. Neurosci. Lett. 193, 53-56.
3. Amin A. R., Vyas P., Attur M., Leszczynska-Piziak J., Patel I. R., Weissmann G., and Abramson S. B. (1995) The mode of action of aspirin-like drugs: effects on inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA 92, 7926-7930.
4. Antiplatelet Trialist's Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308, 81-106.
5. Auphan N., DiDonato J. A., Rosette C., Helmberg A., and Karin M. (1995) Immunosuppression by glucocorticoids: inhibition of NF-κβ activity through induction of IKβ synthesis. Science 270, 286-290.
6. Bowling A. C. and Beal M. F. (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56, 1151-1171.
7. Bradbury A. J., Kelly M. E., Costall B., Naylor R. J., Jenner P., and Marsden G. D. (1985) Benztropine inhibits toxicity of MPTP in mice. Lancet 1, 1444-1445.
8. Breitner J. C. S., Gau B. A., Welsh K. A., Plassman B. L., McDonald W. M., Helms M. J., and Anthony J. C. (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44, 227-232.
9. +. Free Radic. Biol. Med. 13, 581-583.
10. Chiueh C. C., Murphy D. L., Miyake H., Lang K., Tulsi P. K., and Huang S. J. (1993) Hydroxyl free radical (-OH) formation reflected by salicylate hydroxylation and neuromelanin. In vivo markers for oxidant injury of nigral neurons. Ann. NY Acad. Sci. 629, 370-375.
11. Chiueh C. C., Wu R. M., Mohanakumar K. P., Sternberger L. M., Krishna G., Obata T., and Murphy D. L. (1994) In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. NY Acad. Sci. 738, 25-36.
12. Cleeter M. W. J., Cooper J. M., and Schapira A. H. V. (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58, 786-789.
13. Curet O., Damoiseau G., Aubin N., Sontag N., Rovei V., and Jarreau F. X. (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J. Pharmacol. Exp. Ther. 277, 253-264.
14. Dexter D., Carter C. J., Javoy-Agid F., Agid Y., Lees A. J., Jenner P., and Marsden C. D. (1986) Lipid peroxidation as a cause of nigral cell death in Parkinson's disease. Lancet 2, 639-640.
15. Di Monte D. A., Royland J. E., Anderson A., Castagnoli K., Castagnoli N. Jr., and Langston J. W. (1997) Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J. Neurochem. 69, 1771-1773.
16. Fahn S. and Cohen G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32, 804-812.
17. Gaspari F., Perico N., Locatelli M., Corna D., Remuzzi G., and Garattini S. (1989) Renal handling of aspirin in the rat. J. Pharmacol. Exp. Ther. 251, 295-304.
18. Gerlach M., Riederer P., Przuntek H., and Youdim M. B. H. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. Mol. Pharmacol. 208, 273-286.
19. Gerlach M., Youdim M. B. H., and Riederer P. (1996) Pharmacology of selegiline. Neurology 47 (Suppl.), S137-S145.
20. Giovanni A., Liang L. P., Hastings T. G., and Zigmond M. J. (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64, 1819-1825.
21. Grilli M., Pizzi M., Memo M., and Spano P. (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-κβ activation. Science 274, 1383-1385.
22. Halliwell B., Gutteridge J. M. C., and Aruoma O. I. (1987) The deoxyribose method: a simple "test-tube" assay for determination of rate constants for reactions of hydroxyl radicals. Anal. Biochem. 165, 215-219.
23. Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M.-P., Ruberg M., Faucheux B. A., Agid Y., and Hirsch E. C. (1997) Nuclear translocation of NF-κβ is increased in dopaminergic neurones of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA 94, 7531-7536.
24. Jenner P. (1991) Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136, 6-15.
25. Kopp E. and Ghosh S. (1994) Inhibition of NF-κβ by sodium salicylate and aspirin. Science 265, 956-959.
26. Langston J. W. and Ballard P. A. (1983) Parkinson's disease in a chemist working with MPRT. N. Engl. J. Med. 309, 310.
27. Langston J. W., Irwin I., Langston E. B., and Forno L. S. (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225, 1480-1482.
28. Mitchell J. A., Akarasereenont P., Thiemermann C., Flower R. J., and Vane J. R. (1994) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90, 11693-11697.
29. Mizuno Y., Ohta S., Tanaka M., Takiyama S., Suzuki T., Sato T., Oya H., Ozawa T., and Kagawa Y. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455.
30. +) in ventral mesencephalic-striatal co-culture in rat. Neurosci. Lett. 170, 191-194.
31. +. J. Neural Transm. 89, 139-145.
32. Olanow C. W., Hauser R. A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., and Esterlitz J. (1995) The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38, 771-777.
33. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 39, 37-45.
34. Perry T. L., Yong V. W., Clavier R. M., Jones K., Wright J. M., Foulks J. G., and Wall R. A. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109-114.
35. Pileblad E., Fornstedt B., Clark D., and Carlsson A. (1985) Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. J. Pharm. Pharmacol. 37, 707-712.
36. Przedborski S., Jackson Lewis V., Yokoyama R., Shibata T., Dawson V. L., and Dawson T. M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA 93, 4565-4571.
37. Rose S., Nomoto M., Jackson E. A., Gibb W. R., Jenner P., and Marsden C. D. (1989) Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets. Neuropharmacology 28, 1211-1216.
38. Schapira A. H. (1994) Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov. Disord. 9, 125-138.
39. Schapira A. H. V., Cooper J. M., Dexter D., Clark J. B., Jenner P., and Marsden C. D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
40. Schulz J. B., Henshaw D. R., Matthews R. T., and Beal M. F. (1995a) Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132, 279-283.
41. Schulz J. B., Matthews R. T., Muqit M. M. K., Browne S. E., and Beal M. F. (1995b) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64, 936-939.
42. Snyder S. H. and D'Amato R. J. (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36, 250-258.
43. Sriram K., Pai K. S., Boyd M. R., and Ravindranath V. (1997) Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749, 44-52.
44. Tatton W. G., Lu W. Y. L., Holland D. P., Tai C., and Kwan M. (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63, 1572-1575.
45. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
46. Vaux D. L. and Strasser A. (1996) The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA 93, 2239-2244.
47. Wright S. C., Kumar P., Tam A. W., Shen N., Varma M., and Larrick J. W. (1992) Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. J. Cell. Biochem. 48, 344-355.
48. Zang L.-Y. and Misra H. P. (1993) Generation of reactive oxygen species during the monoamine-oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Biol. Chem. 268, 16504-16512.